You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
FACTOR V LEIDEN MUTATION ANALYSIS, PCR |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2255 Geisinger Epic ID: 53657 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Whole blood | |
Preferred collection container: |
||
Specimen required: |
3 mL lavendar-top EDTA whole blood; minimum 0.5 mL. NO SHARED SPECIMENS WITH OTHER LABORATORY DEPARTMENTS. May be combined with other Molecular Diagnostic tests. For genetic testing, original tube required. | |
Special notes: |
Mix well immediately. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Do not centrifuge. | |
Transport temperature: |
Refrigerate (2-8°C). | |
Specimen stability: |
Stable at room temperature for 24 hours; stable at 2-8°C (refrigerated) for 15 days. | |
Rejection criteria: |
Stability limits exceeded. Shared or comingled specimens. | |
TEST DETAILS |
||
Reference interval: |
Negative. | |
Additional information: |
For genetic tesing, original tube required. | |
CPT code(s): |
81241 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Factor V Leiden mutation. | |
Methodology: |
Real-time Polymerase Chain Reaction (PCR) |
|
Synonyms: |
Factor V mutation, factor V PCR, factor V DNA, factor V Leiden mutation, R506Q mutation PFVLM, Factor V, Factor V DNA analysis, FVLM PCR, FVLM DNA
|
|
Clinical significance: |
Factor V Leiden is a common cause of inherited thrombophilia. The R506Q mutation leads to resistance of degradation of the factor V protein by activated protein C (APC). Heterozygotes, or individuals who have one copy of the mutation, carry a 2- to 10-fold increased risk of venous thrombosis. Homozygotes, or individuals who have two copies of the mutation, carry a >10-fold increased risk. | |
Doctoral Director(s:) |
Yi Ding MD, PhD | |
| Review Date: | 12/20/2022 | |